Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way

Kyle Blankenship

After a long-awaited approval for its CD19 targeting CAR-T liso-cel, Bristol Myers Squibb is gearing up for the looming review of another cell therapy in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way

Kyle Blankenship

Sign up to read this article for free.

ADC scientist who paved the way for Daiichi’s Enhertu dies

AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

Biosecure bill is left out of end-of-year defense package, dealing blow to chances

Beam shares results from seven patients who received gene-edited sickle cell therapy

Dutch biotech nabs €85M to position inflammatory antibody for a pharma buyer

The key to faster, more impactful research? Put patients in the driver’s seat

Bris­tol My­ers scales up cell ther­a­py pro­duc­tion with liso-cel nod in hand and an­oth­er ap­proval maybe on the way

Kyle Blankenship

Sign up to read this article for free.

ADC sci­en­tist who paved the way for Dai­ichi’s En­her­tu dies

As­traZeneca re­veals first clin­i­cal da­ta for bis­pe­cif­ic T cell en­gager from TeneoT­wo buy­out

Biose­cure bill is left out of end-of-year de­fense pack­age, deal­ing blow to chances

Beam shares re­sults from sev­en pa­tients who re­ceived gene-edit­ed sick­le cell ther­a­py

Dutch biotech nabs €85M to po­si­tion in­flam­ma­to­ry an­ti­body for a phar­ma buy­er

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way

ADC scientist who paved the way for Daiichi’s Enhertu dies

AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

Biosecure bill is left out of end-of-year defense package, dealing blow to chances

Beam shares results from seven patients who received gene-edited sickle cell therapy

Dutch biotech nabs €85M to position inflammatory antibody for a pharma buyer

The key to faster, more impactful research? Put patients in the driver’s seat